Literature DB >> 30370142

Adjuvant targeted therapy for resected NSCLC: to be or not to be?

Ting Ye1,2, Haiquan Chen1,2.   

Abstract

Entities:  

Year:  2018        PMID： 30370142      PMCID： PMC6186608          DOI： 10.21037/jtd.2018.07.111

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  12 in total

1.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

2.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Authors:  Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; Shucai Zhang; Jie Wang; Songwen Zhou; Shengxiang Ren; Shun Lu; Li Zhang; Chengping Hu; Chunhong Hu; Yi Luo; Lei Chen; Ming Ye; Jianan Huang; Xiuyi Zhi; Yiping Zhang; Qingyu Xiu; Jun Ma; Li Zhang; Changxuan You
Journal:  Lancet Oncol       Date:  2011-07-23       Impact factor: 41.316

Review 3.  Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program.

Authors:  Lynn A Gloeckler Ries; Marsha E Reichman; Denise Riedel Lewis; Benjamin F Hankey; Brenda K Edwards
Journal:  Oncologist       Date:  2003

4.  Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.

Authors:  Katherine M W Pisters; William K Evans; Christopher G Azzoli; Mark G Kris; Christopher A Smith; Christopher E Desch; Mark R Somerfield; Melissa C Brouwers; Gail Darling; Peter M Ellis; Laurie E Gaspar; Harvey I Pass; David R Spigel; John R Strawn; Yee C Ung; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

5.  Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.

Authors:  R Arriagada; A Auperin; S Burdett; J P Higgins; D H Johnson; T Le Chevalier; C Le Pechoux; M K B Parmar; J P Pignon; R L Souhami; R J Stephens; L A Stewart; J F Tierney; H Tribodet; J van Meerbeeck
Journal:  Lancet       Date:  2010-03-24       Impact factor: 79.321

6.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

7.  Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Authors:  Glenwood D Goss; Chris O'Callaghan; Ian Lorimer; Ming-Sound Tsao; Gregory A Masters; James Jett; Martin J Edelman; Rogerio Lilenbaum; Hak Choy; Fadlo Khuri; Katherine Pisters; David Gandara; Kemp Kernstine; Charles Butts; Jonathan Noble; Thomas A Hensing; Kendrith Rowland; Joan Schiller; Keyue Ding; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

8.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Consensus conference: multimodality management of early- and intermediate-stage non-small cell lung cancer.

Authors:  Rodolfo Bordoni
Journal:  Oncologist       Date:  2008-09-08

10.  Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Authors:  Wen-Zhao Zhong; Qun Wang; Wei-Min Mao; Song-Tao Xu; Lin Wu; Yi Shen; Yong-Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Ke Fei; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Hong-Hong Yan; Xue-Ning Yang; Qing Zhou; Yi-Long Wu
Journal:  Lancet Oncol       Date:  2017-11-21       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.